UK Markets close in 4 hrs 42 mins

Merck KGaA's lab supplies unit sees Q3 EBITDA jump 30.7%

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
FILE PHOTO: The logo of German pharmaceuticals company Merck is seen at the company's headquarters in Darmstadt
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

FRANKFURT (Reuters) - Germany's Merck KGaA said its Life Science unit, which supplies materials and gear to makers of vaccines and drugs, saw adjusted earnings jump 30.7% in the third quarter, driven by demand related to COVID-19.

Earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-off items, for the division reached 824 million euros, the diversified group reported on Thursday.

In an unscheduled release last week, Merck raised its full-year profit forecast, citing very strong performance at its Life Science unit, and published forecast-beating group earnings for the quarter.

(Reporting by Ludwig Burger)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting